Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Mar 1;180(3):376-384.
doi: 10.1001/jamainternmed.2019.6108.

Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Gulraj S Matharu  1 , Setor K Kunutsor  1   2 , Andrew Judge  1   2 , Ashley W Blom  1   2 , Michael R Whitehouse  1   2
Affiliations
Meta-Analysis

Clinical Effectiveness and Safety of Aspirin for Venous Thromboembolism Prophylaxis After Total Hip and Knee Replacement: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Gulraj S Matharu et al. JAMA Intern Med. .

Abstract

Importance: Patients undergoing total hip replacement (THR) and total knee replacement (TKR) receive venous thromboembolism (VTE) pharmacoprophylaxis. It is unclear which anticoagulant is preferable. Observational data suggest aspirin provides effective VTE prophylaxis.

Objective: To assess the effectiveness and safety of aspirin for VTE prophylaxis after THR and TKR.

Data sources: A systematic review and meta-analysis was performed of randomized clinical trials (RCTs), with no language restrictions, from inception to September 19, 2019, using MEDLINE, Embase, Web of Science, Cochrane Library, and bibliographic searches. The computer-based searches combined terms and combinations of keywords related to the population (eg, hip replacement, knee replacement, hip arthroplasty, and knee arthroplasty), drug intervention (eg, aspirin, heparin, clexane, dabigatran, rivaroxaban, and warfarin), and outcome (eg, venous thromboembolism, deep vein thrombosis, pulmonary embolism, and bleeding) in humans.

Study selection: This study included RCTs assessing the effectiveness and safety of aspirin for VTE prophylaxis compared with other anticoagulants in adults undergoing THR and TKR. The RCTs with a placebo control group were excluded. The searches and study selection were independently performed.

Data extraction and synthesis: This study followed PRISMA recommendations and used the Cochrane Collaboration's risk of bias tool. Data were screened and extracted independently by both reviewers. Study-specific relative risks (RRs) were aggregated using random-effects models. Quality of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.

Main outcomes and measures: The primary outcome was any postoperative VTE (asymptomatic or symptomatic). Secondary outcomes were adverse events associated with therapy, including bleeding.

Results: Of 437 identified articles, 13 RCTs were included (6060 participants; 3466 [57.2%] women; mean age, 63.0 years). The RR of VTE after THR and TKR was 1.12 (95% CI, 0.78-1.62) for aspirin compared with other anticoagulants. Comparable findings were observed for deep vein thrombosis (DVT) (RR, 1.04; 95% CI, 0.72-1.51) and pulmonary embolism (PE) (RR, 1.01; 95% CI, 0.68-1.48). The risk of adverse events, including major bleeding, wound hematoma, and wound infection, was not statistically significantly different in patients receiving aspirin vs other anticoagulants. When analyzing THRs and TKRs separately, there was no statistically significant difference in the risk of VTE, DVT, and PE between aspirin and other anticoagulants. Aspirin had a VTE risk not statistically significantly different from low-molecular-weight heparin (RR, 0.76; 95% CI, 0.37-1.56) or rivaroxaban (RR, 1.52; 95% CI, 0.56-4.12). The quality of the evidence ranged from low to high.

Conclusions and relevance: In terms of clinical effectiveness and safety profile, aspirin did not differ statistically significantly from other anticoagulants used for VTE prophylaxis after THR and TKR. Future trials should focus on noninferiority analysis of aspirin compared with alternative anticoagulants and cost-effectiveness.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Matharu reported receiving personal fees from Leigh Day for medicolegal work. Dr Judge reported receiving personal fees from Anthera Pharmaceuticals, Inc, Freshfields, Bruckhaus, and Deringer. Dr Blom reported receiving grants from Stryker. Dr Whitehouse reported receiving grants from the National Joint Registry, National Institute for Health Research (NIHR) Bristol Biomedical Research Centre, NIHR, and Stryker and receiving teaching support from Hearaeus and DePuy. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. PRISMA Flow Diagram
NICE indicates UK National Institute for Health and Care Excellence; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses.
Figure 2.
Figure 2.. Effectiveness of Aspirin Compared With Other Anticoagulants on Venous Thromboembolism (Including Deep Vein Thrombosis and Pulmonary Embolism) in Randomized Clinical Trials of Patients Undergoing Total Hip and Knee Replacement
Thirteen randomized clinical trials,,,,,,,,,,,, were included. Outcomes included both symptomatic and asymptomatic venous thromboembolism events. The summary estimate presented was calculated using a random-effects model. Sizes of data markers are proportional to the inverse of the variance of the relative ratio. RR indicates relative risk. The diamonds represent the overall estimated relative risk (with 95% CIs) for the 13 trials combined when using a random-effects model and when using a fixed-effects model.
Figure 3.
Figure 3.. Effectiveness of Aspirin Compared With Other Anticoagulants on Venous Thromboembolism (VTE) in Randomized Clinical Trials of Patients Undergoing Total Hip and Knee Replacement, Grouped According to Study-Level Characteristics
Thirteen randomized clinical trials,,,,,,,,,,,, were included. Outcomes included both symptomatic and asymptomatic VTE events. P values are for meta-regression. DVT indicates deep vein thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; RCT, randomized clinical trial; RR, relative risk; THR, total hip replacement; and TKR, total knee replacement.
See this image and copyright information in PMC

Comment in

  • Nach TEP nur ASS gegen Thrombosen?
    Parhofer KG. Parhofer KG. MMW Fortschr Med. 2020 Mar;162(5):30. doi: 10.1007/s15006-020-0252-y. MMW Fortschr Med. 2020. PMID: 32189271 Review. German. No abstract available.

References

    1. Learmonth ID, Young C, Rorabeck C. The operation of the century: total hip replacement. Lancet. 2007;370(9597):1508-1519. doi:10.1016/S0140-6736(07)60457-7 - DOI - PubMed
    1. Select Committee on Health Written Evidence Appendix 6. https://publications.parliament.uk/pa/cm200405/cmselect/cmhealth/99/99we.... Accessed December 28, 2019.
    1. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 2001;358(9275):9-15. doi:10.1016/S0140-6736(00)05249-1 - DOI - PubMed
    1. Bala A, Huddleston JI III, Goodman SB, Maloney WJ, Amanatullah DF. Venous thromboembolism prophylaxis after TKA: aspirin, warfarin, enoxaparin, or factor Xa inhibitors? Clin Orthop Relat Res. 2017;475(9):2205-2213. doi:10.1007/s11999-017-5394-6 - DOI - PMC - PubMed
    1. Parvizi J, Ceylan HH, Kucukdurmaz F, Merli G, Tuncay I, Beverland D. Venous thromboembolism following hip and knee arthroplasty: the role of aspirin. J Bone Joint Surg Am. 2017;99(11):961-972. doi:10.2106/JBJS.16.01253 - DOI - PubMed

Publication types

MeSH terms